Tue, Sep 2, 2014, 6:34 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

  • kaylawa kaylawa Nov 19, 2012 10:21 AM Flag

    Forbes out with Neg commentary on Amarin (and Lovaza)

    "Could a Fish Oil Backlash Wash Out Amarin" . Negative slant on "fish oil" and falling Lovaza prescriptions. Think he misses the pure EPA point and yes, Lovaza prescriptions will fall even further. ;)
    Forbes.c??/sites/matthewherper/2012/11/19/could-a-fish-oil-backlash-wash-out-amarin-pharmaceuticals/

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Note no nutritionist quoted. Md's are not really trained in nutrition. This makes it harder for them to understand the value of Vascepa. Patient demand will enlighten them in a hurry.

      Sentiment: Buy

    • Just read the article and was all set to refute it (burn it, actually), but I see all you guys more than covered it. 8)

      Sentiment: Strong Buy

    • Herper and Feuerstein are the same guy, right?! What a couple of bozos.

      Sentiment: Strong Buy

    • This is not new and has been written about for the last 18 months. That said, there has not been
      a difinitve trial, (PH III Protocol) done to answer the question about the efficacy of Lovaza or any other Omega 3 Oil. FDA requested AMRN do the PH IV trial with Crestor and Vascepa to see if the
      adverse cardiovascular event incidence of statins, can be further lowered by adding Vascepa. .
      When this trial is 40% enrolled, AMRN will be given an approval for Mixed Dyslipidemia,(combined use with statins). The Forbes piece uses a meta analyis,, a retrspective look at pooled trials which is not considered of merit.. In the mean time Cardiologists will still write for an effcacious drug like Vasepa as opposed to a minimally effective drug like Lovaza, which is problematic because of slightly raising A Lipo B , and LDL.

      Sentiment: Strong Buy

    • This is a repeat of other similiar stories talking about studies with over the counter fish oil. As for the Doctor quoted in the article stating she would just tell people to eat more fish, what a quack.

    • It is unfortunate that articles like this that cite studies which have been heavily discounted and refer to unnamed sources (a group of 1 perhaps) get published by respected organizations without peer review. Notice that although the % sales of Lovaza is not increasing as fast as originally, however, it is still increasing and the total sales are huge.... (and this market will be Vascepa's). How many high cholersterol patients are going to rely just on Whole Foods fish oil supplements? Do you (collective you) know anyone with these high cholesterol levels just punting along trying out what is in GNC and other places???? This is such a poorly written and slanted article. But, once again instead of intelligent analysis we get a lot of journalistic hype from someone who has only limited understanding.

      Sentiment: Strong Buy

    • Kayla and Livin ---thanks for all the DD on the patents .
      Re the Forbes article --
      No doubt MD's are experiencing frustration with the problems presented by the current TG lowering Meds.
      The outcome trials for Niacin , Fibrates and low dose EPA/DHA Omega 3's have shown little clinical benefit. All of these TG lowering drugs have side effects and present the risk of raising LDL cholesterol.
      So why prescribe Vascepa ?
      From the Cardiologists I talk to it comes down to the following
      1) They believe lowering TG's to below 150 reduces risk of CV events --citing data from the Prove -it Trial.
      2) While they don't know if lowering TG's by prescribing Vascepa at 4 gm doses will reduce events until the Reduce it outcome trial results ----they see little risk in prescribing it.

      Simply put as one Cardiologist said to me " It ( Vascepa ) won't hurt you , it may help you --so I'll prescribe it for you "
      Akanz

      Sentiment: Buy

      • 3 Replies to akanz2
      • |It may help you? There have been trials run to prove that it will help you

      • Your last sentence is the same sentiment that 99% of Cardiologists will follow (plus family Doctors will also recommend investigating this at least). The Forbes article refers to the 1% (or less) and makes it seem like this is the majority. Again we have a patent issued combined with a poorly researched and slanted article coming out at the same time so have to wait for the dust to settle (and the share price will rebound of course as always). Feuerberg has the same impact so an article by Forbes will too. Pretty pathetic though that such nonsense gets printed as news... but happens every day in Politics right?

        Sentiment: Strong Buy

      • PS --- I should mention that I had discussed the Jelis trial with the Cardiologist I referred to above . He said he was aware of the trial but it was in a Japanese population with a high fish intake as part of their regular diet . He wanted to see the results in a US population that traditionally had a very low fish intake in their diet . ( Or if it was fish --the wrong fish ie fried Cat fish )

        Nevertheless --he was going to prescribe Vascepa instead of Lovaza, Niacin or Fibrates as a way to lower TG's as he saw little risk in doing so and possible benefit.
        Akanz

        Sentiment: Buy

    • Should create a lot more demand for Vecepa with this concern since iot soesn't apply to Vacepa.

      Sentiment: Strong Buy

    • http://www.forbes.com/sites/matthewherper/2012/11/19/could-a-fish-oil-backlash-wash-out-amarin-pharmaceuticals/

    • Oh the talking heads out there, they create nothing, research little and speculate endlessly - it's a posturing world where these scurvy little spiders (which movie?) come out bright and early to spew in total manipulation. Amazing that with all that is going on in the heavy-hitting world and market, these little snot-nosed toadies (AF) curiously choose a sissified cat scratch at a future blockbuster, a prime entity, that is actually going to take the next big step in heart health. The grand manipulation by the talentless...Bernie's market is a good place to find 'em.

      Sentiment: Strong Buy

    • View More Messages
 
AMRN
1.925-0.005(-0.26%)Sep 2 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.